Intercept Pharmaceuticals Inc. Reaches New 12-Month High at $305.00 (ICPT)
Intercept Pharmaceuticals (NASDAQ:ICPT)’s share price reached a new 52-week high during mid-day trading on Thursday, Analyst Ratings Network reports. The stock traded as high as $305.00 and last traded at $274.01, with a volume of 6,172,672 shares traded. The stock had previously closed at $72.39.
Separately, analysts at BMO Capital Markets raised their price target on shares of Intercept Pharmaceuticals to $270.00 in a research note to investors on Thursday. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $106.80.
Intercept Pharmaceuticals has a 52 week low of $30.38 and a 52 week high of $77.53. The stock has a 50-day moving average of $60.17 and a 200-day moving average of $53.73. The company’s market cap is $5.306 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Thursday, November 14th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $1.14. During the same quarter in the previous year, the company posted ($1.86) earnings per share. On average, analysts predict that Intercept Pharmaceuticals will post $-3.45 earnings per share for the current fiscal year.
Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.